Quantification of tumor heterogeneity: from data acquisition to metric generation
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Tumors are unique and complex ecosystems, in which heterogeneous cell subpopulations with variable molecular profiles, aggressiveness, and proliferation potential coexist and interact.Understanding how heterogeneity influences tumor progression has important clinical implications for improving diagnosis, prognosis, and treatment response prediction.Several recent innovations in data acquisition methods and computational metrics have enabled the quantification of spatiotemporal heterogeneity across different scales of tumor organization.Here, we summarize the most promising efforts from a common experimental and computational perspective, discussing their advantages, shortcomings, and challenges.With personalized medicine entering a new era of unprecedented opportunities, our vision is that of future workflows integrating across modalities, scales, and dimensions to capture intricate aspects of the tumor ecosystem and to open new avenues for improved patient care. Tumor heterogeneity: scales, dimensions, and implicationsTissue architecture is organized functionally, with several cell subpopulations (see Glossary) contributing with distinct roles in maintaining homeostasis.At the onset of oncogenesis, tissue organization is disrupted by an uncontrolled splurge of genetically unstable cell subpopulations in a limited spatial niche.Increased genomic variability gradually translates to elevated phenotypic and functional variability, contributing to what is commonly referred to as tumor heterogeneity.As these heterogeneous subpopulations expand and interact with one another and their microenvironment, they generate cancer ecosystems, following evolutionary principles of traditional ecology [1].From the inner workings of a single cell to the patterns observed at a population level, heterogeneity is omnipresent across all scales of tumor organization.Stemming from intrinsic genetic instability and further amplified by other sources of variability at the epigenetic, transcriptional, or protein levels, tumor heterogeneity manifests in both a spatial and temporal dimension [2] (Figure 1).Temporal heterogeneity is present in the dynamic processes underlying cancer initiation, evolution, and metastasis [3].Spatial heterogeneity describes the complex tumor architecture, notably the interplay between cancer, immune, or stromal cells, and access to nutrients and growth factors through the vasculature or regional hypoxia [4].Moving up the scale of complexity, heterogeneity leads to spatiotemporal variability in tumor size, shape, texture, and organ localization, both within and across patients.Tumor heterogeneity has a substantial impact on treatment response and disease outcome [5,6].Given that cancer cells constantly evolve disease progression mechanisms or treatment escape routes [7], monitoring and quantifying tumor heterogeneity at diagnosis, during treatment, and possibly during disease resistance, is vital.To address this need, a plethora of data acquisition Highlights Understanding tumor complexity and applying that knowledge to advance patient care is a cornerstone of cancer research.However, tumor heterogeneity obfuscates this vision.Contemporary research contains a diverse set of technologies and computational tools for detecting, characterizing, and quantifying tumor heterogeneity at the molecular, architectural, organ, patient, or population level.Evaluation of the clinical relevance of heterogeneity metrics and creating actionable intelligence for the clinics, requires a common lexicon across disciplines, and a unified look toward multimodal data acquisition and computational analysis, the constraints they present, and how they partake in whole workflows.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massively parallel digital transcriptional profiling of single cells
Zheng, G. X. Y., Terry, J. M., Belgrader, P., Ryvkin, P., Bent, Z. W., Wilson, R., Ziraldo, S. B., Wheeler, T. D., McDermott, G. P., Zhu, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14049 · Cited by 7,353
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132 · cited 3×
“A second issue of Esophageal cancer [141] Colorectal cancer [142] Pancreatic cancer [143] Gastric cancer [144] Lung and head-and-neck cancer [150] Clear cell renal cell carcinoma [152] PET Cervix and head and neck cancer [157] Esophageal carcinoma [158] Lung cancer [159] MRI Breast cancer [164 –…”
BackgroundSpatially resolved, highly multiplexed RNA profiling in single cells
Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S., & Zhuang, X. (2015) · Science · doi:10.1126/science.aaa6090 · Cited by 2,969
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Opportunities and challenges in long-read sequencing data analysis
Amarasinghe, S. L., Su, S., Dong, X., Zappia, L., Ritchie, M. E., & Gouil, Q. (2020) · Genome Biology · doi:10.1186/s13059-020-1935-5 · Cited by 2,530
Ripley, B. D. (1977) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1977.tb01615.x · Cited by 2,511 · cited 1×
“Ripley ’ s K (see Tables 3 and 4 in the main text) quanti fi es to what extent cell type distributions (events) show a random, clustered, or dispersed pattern in space [187], de fi ned as a function of the density of the observed events at various distances r .”
BackgroundSlide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution
Rodriques, S. G., Stickels, R. R., Goeva, A., Martin, C. A., Murray, E., Vanderburg, C. R., Welch, J., Chen, L. M., Chen, F., & Macosko, E. Z. (2019) · Science · doi:10.1126/science.aaw1219 · Cited by 2,424
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066 · cited 1×
“Geiss et al. [41] developed the nCounter system, which comprises barcoding and labeling of mRNA transcripts in tissue using a color-coded probe pair (DNA oligo backbone + sequence speci fi c RNAoligo), which allows for user-controlled ampli fi cation and detection sensitivity using PCR.”
MethodHighly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
Giesen, C., Wang, H. A. O., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., Schüffler, P. J., Grolimund, D., Buhmann, J. M., Brandt, S., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2869 · Cited by 1,951
Integrative single-cell analysis
Stuart, T., & Satija, R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0093-7 · Cited by 1,460
The sequence of sequencers: The history of sequencing DNA
Heather, J. M., & Chain, B. (2016) · Genomics · doi:10.1016/j.ygeno.2015.11.003 · Cited by 1,397
Eleven grand challenges in single-cell data science
Lähnemann, D., Köster, J., Szczurek, E., McCarthy, D. J., Hicks, S. C., Robinson, M. D., Vallejos, C. A., Campbell, K. R., Beerenwinkel, N., Mahfouz, A., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-1926-6 · Cited by 1,327
Bandura, D. R., Baranov, V. I., Ornatsky, O. I., Antonov, A., Kinach, R., Lou, X., Pavlov, S., Vorobiev, S., Dick, J. E., & Tanner, S. D. (2009) · Analytical Chemistry · doi:10.1021/ac901049w · Cited by 1,295
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191 · cited 1×
“With respect to new molecules, plasma-free cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) extracted from patient blood (liquid biopsy) are seeing limited use in identifying genomic targets for therapy and drug monitoring [76] and need to be further validated for pervasive clinical use.”
BackgroundKeren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183
Multiplexed ion beam imaging of human breast tumors
Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Highly Multiplexed Subcellular RNA Sequencing in Situ
Lee, J. H., Daugharthy, E. R., Scheiman, J., Kalhor, R., Yang, J. L., Ferrante, T. C., Terry, R., Jeanty, S. S. F., Li, C., Amamoto, R., et al. (2014) · Science · doi:10.1126/science.1250212 · Cited by 973
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?
Davnall, F., Yip, C. S. P., Ljungqvist, G., Selmi, M., Ng, F., Sanghera, B., Ganeshan, B., Miles, K. A., Cook, G. J., & Goh, V. (2012) · Insights into Imaging · doi:10.1007/s13244-012-0196-6 · Cited by 878 · cited 2×
“Moreover, such metrics are dependent on medical equipment and effect of image acquisition, quality of clinical images, and software used for feature extraction [176].”
BackgroundScaling single-cell genomics from phenomenology to mechanism
Tanay, A., & Regev, A. (2017) · Nature · doi:10.1038/nature21350 · Cited by 792
Decoding global gene expression programs in liver cancer by noninvasive imaging
Segal, E., Sirlin, C. B., Ooi, C., Adler, A. S., Gollub, J., Chen, X., Chan, B. K., Matcuk, G. R., Barry, C. T., Chang, H. Y., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1306 · Cited by 629 · cited 1×
“Similarly, gene expression patterns correlate with dynamic imaging features in liver cancer CT scans [151], and histogram and Haralick texture features computed from CT images were predictive of BAP1 mutation status in clear cell renal cell carcinoma [152].”
BackgroundTumour heterogeneity and metastasis at single-cell resolution
Lawson, D. A., Kessenbrock, K., Davis, R. T., Pervolarakis, N., & Werb, Z. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0236-7 · Cited by 606
Design and Analysis of Single-Cell Sequencing Experiments
Grün, D., & van Oudenaarden, A. (2015) · Cell · doi:10.1016/j.cell.2015.10.039 · Cited by 536 · cited 1×
“The classical technique of fl ow cytometry [21] has inspired a plethora of single cell platforms [22] that compartmentalize individual cells using micro fl uidics, microelectromechanical, and micrototal analysis ( μ TAS) technologies [11].”
MethodHighly multiplexed in situ protein imaging with signal amplification by Immuno-SABER
Saka, S. K., Wang, Y., Kishi, J. Y., Zhu, A., Zeng, Y., Xie, W., Kirli, K., Yapp, C., Cicconet, M., Beliveau, B. J., et al. (2018) · doi:10.1101/507566 · Cited by 485
Spatial Heterogeneity in the Tumor Microenvironment
Yuan, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026583 · Cited by 342
Highly multiplexed simultaneous detection of RNAs and proteins in single cells
Frei, A. P., Bava, F.-A., Zunder, E. R., Hsieh, E. W. Y., Chen, S.-Y., Nolan, G. P., & Gherardini, P. F. (2016) · Nature Methods · doi:10.1038/nmeth.3742 · Cited by 330 · cited 1×
“Examples include scRNA-seq for multi-omic pro fi ling [69] and previously mentioned spatial methods, such as SABER [70] or the related PLAYR [71], adapted for multi-omic capture.”
MethodChakraborty, J., Langdon-Embry, L., Cunanan, K. M., Escalon, J. G., Allen, P. J., Lowery, M. A., O’Reilly, E. M., Gönen, M., Do, R. G., & Simpson, A. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188022 · Cited by 85
Comparison of whole genome amplification techniques for human single cell exome sequencing
Borgström, E., Paterlini, M., Mold, J. E., Frisen, J., & Lundeberg, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171566 · Cited by 77 · cited 1×
“…genomic analysis, these platforms can be used for single cell DNA sequencing (DNA-seq) with an intermediate whole-genome ampli fi cation (WGA) step [32] that uses degenerate or universal priming to amplify the DNA content of a single cell, which is then input into the forementioned sequencing work…”
Method
Cited by
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158
“At the pathological level, computational algorithms such as hypergeometric probabilities and entropic indices, including Shannon, Simpson, and the grey-level co-occurrence matrix, have been developed to better quantify PSMA heterogeneity 97 .”
Explainable artificial intelligence for drug discovery and development: a comprehensive survey
Alizadehsani, R., Oyelere, S. S., Hussain, S., Jagatheesaperumal, S. K., Calixto, R. R., Rahouti, M., Roshanzamir, M., & De Albuquerque, V. H. C. (2024) · IEEE Access · doi:10.1109/access.2024.3373195 · Cited by 124
Li, J., Li, L., You, P., Wei, Y., & Xu, B. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.009 · Cited by 55
Metadata
- Authors
- Kashyap, A., Rapsomaniki, M. A., Barros, V., Fomitcheva-Khartchenko, A., Martinelli, A. L., Rodriguez, A. F., Gabrani, M., Rosen-Zvi, M., & Kaigala, G.
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 40
- Issue
- 6
- Pages
- 647-676
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W4200324152
- Cited by
- 98
- References
- 29
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.